Insmed Inc
Q4 2025 Earnings
Market Reaction
S&P 500 over the same 30 days: −4.25%.
Did INSM Beat Earnings? Q4 2025 Results
Insmed delivered a mixed fourth quarter for fiscal 2025, posting revenue that landed essentially in line with expectations while absorbing a notably wider-than-anticipated loss. The company reported Q4 revenue of $263.84 million, a 152.6% year-over-year surge fueled by the commercial launch of BRINSUPRI for non-cystic fibrosis bronchiectasis, which generated $144.60 million in its first full quarter of U.S. sales, while ARIKAYCE contributed $119.20 million. Yet the earnings picture was harder to overlook: Insmed recorded a loss of $1.54 per share, missing the consensus estimate of $1.17 by roughly 31.92%, as R&D spending climbed to $254.91 million and SG&A reached $212.48 million amid heavy commercialization investment, compounded by a $70.04 million fair-value charge on contingent consideration liabilities. Analysts tracking commercial execution have kept a close eye on the BRINSUPRI ramp, and Insmed rewarded that attention by guiding for at least $1.00 billion in BRINSUPRI revenues and $450.00 to $470.00 million from ARIKAYCE in 2026, implying total revenues of at least $1.45 billion.
- Strong U.S. commercial launch of BRINSUPRI exceeding expectations in first full quarter
- ARIKAYCE 19% annual global revenue growth exceeding upper end of 2025 guidance
- ARIKAYCE international revenue grew 41% year-over-year for full-year 2025
- Cost of product revenues as percentage of sales improved to 16.8% from 25.0% due to BRINSUPRI's lower manufacturing cost
- Approximately 4,000 cumulative BRINSUPRI prescribers as of December 31, 2025
- Over 90% of targeted patient lives have access to BRINSUPRI reimbursement
“As we close out 2025 and begin an exciting new year at Insmed, I am energized by the significant opportunities ahead to serve patients with serious diseases. Our U.S. commercial launch of BRINSUPRI continues to exceed our expectations, and we are proud to provide this medicine to patients who previously had no approved treatment for their disease. Throughout 2026, we will continue to bring BRINSUPRI to patients with bronchiectasis, expand our Phase 3 clinical programs for TPIP, and advance our early-stage pipeline, fueling the research engine that we hope will power the next wave of potentially life-transforming therapies for patients.”
Insmed CEO, on the earnings call
Forward Guidance & Outlook
Insmed expects full-year 2026 BRINSUPRI revenues of at least $1 billion and reiterates ARIKAYCE revenue guidance of $450 million to $470 million, implying total company revenues of at least $1.45 billion (~139% growth over 2025). BRINSUPRI gross-to-net is expected in the mid-20%s to low-30%s range, while ARIKAYCE gross-to-net is guided at low-20%s to mid-20%s. Management is confident cash flow positivity can be achieved without raising additional capital, though may raise capital for business development or other value-creating initiatives. Pre-clinical research programs are expected to comprise less than 20% of overall expenditures. Key clinical catalysts include the Phase 3 ENCORE topline readout for ARIKAYCE in MAC lung disease in March/April 2026, Phase 2b CEDAR topline data for brensocatib in HS in Q2 2026, and initiation of Phase 3 TPIP study in PAH in H1 2026.
INSM YoY Financials
INSM Revenue by Segment
INSM Revenue by Geography
Figures from SEC filings and company reports. Not investment advice.